

# Product Information Sheet for MRA-880A

## Monoclonal Anti-*Plasmodium falciparum*, Merozoite Specific Protein 1 (MSP1), Clone 5D5/47 (produced in vitro)

### Catalog No. MRA-880A

This reagent is the tangible property of the U.S. Government.

### For research use only. Not for use in humans.

#### Contributor:

Allan Saul, Ph.D., Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA

#### Manufacturer:

BEI Resources

#### Product Description:

Antibody Class: IgG1k

Mouse monoclonal antibody prepared against the merozoite surface protein 1 (MSP1) of *Plasmodium falciparum* was purified from clone 5D5/47 hybridoma supernatant using protein G affinity chromatography. The B cell hybridoma was generated by the fusion of P3/NS1/1/AG4/1 mouse myeloma cells with splenocytes from immunized mice.

#### Material Provided:

Each vial of MRA-880A contains approximately 100 µL of purified monoclonal antibody in phosphate-buffered saline (PBS). The concentration, expressed as mg/mL, is shown on the Certificate of Analysis.

#### Packaging/Storage:

MRA-880A was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

#### Functional Activity:

Monoclonal antibody 5D5/47 is specific for the merozoite surface protein 1 of *Plasmodium falciparum* FCQ27/PNG.<sup>1,2</sup>

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-*Plasmodium falciparum* Merozoite Specific Protein 1 (MSP1), Clone 5D5/47 (produced in vitro), MRA-880A, contributed by Allan Saul."

#### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL\)](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

#### References:

1. Saul, A., Personal Communication.
2. Cooper, J. A., L. T. Cooper and A. J. Saul. "Mapping of the Region Predominantly Recognized by Antibodies to the *Plasmodium falciparum* Merozoite Surface Antigen MSA." *Mol. Biochem. Parasitol.* 51 (1992): 301-312. PubMed: 1574088.
3. Malkin, E., et al. "Phase 1 Study of Two Merozoite Surface Protein 1 (MSP1<sub>42</sub>) Vaccines for *Plasmodium falciparum* Malaria." *PLoS Clin. Trials* 2 (2007): e12. PubMed: 17415408.

ATCC® is a trademark of the American Type Culture Collection.

